Document
IPR2022-01524, No. 1047 Exhibit - 1047 Regeneron 18 February 2010 (P.T.A.B. Sep. 9, 2022)
Cite Document
IPR2022-01524, No. 1047 Exhibit - 1047 Regeneron 18 February 2010 (P.T.A.B. Sep. 9, 2022)
+ More Snippets
Document
IPR2022-01524, No. 1052 Exhibit - 1052 Ciulla (P.T.A.B. Sep. 9, 2022)
Cite Document
IPR2022-01524, No. 1052 Exhibit - 1052 Ciulla (P.T.A.B. Sep. 9, 2022)
+ More Snippets
Document
IPR2022-01524, No. 1012 Exhibit - 1012 Monthly Dosing Patents (P.T.A.B. Sep. 9, 2022)
Cite Document
IPR2022-01524, No. 1012 Exhibit - 1012 Monthly Dosing Patents (P.T.A.B. Sep. 9, 2022)
+ More Snippets
Document
IPR2022-01524, No. 1037 Exhibit - 1037 Ferrara 2005 (P.T.A.B. Sep. 9, 2022)
Cite Document
IPR2022-01524, No. 1037 Exhibit - 1037 Ferrara 2005 (P.T.A.B. Sep. 9, 2022)
+ More Snippets
Document
IPR2022-01524, No. 1021 Exhibit - 1021 History ClinicalTrialsgov (P.T.A.B. Sep. 9, 2022)
Cite Document
IPR2022-01524, No. 1021 Exhibit - 1021 History ClinicalTrialsgov (P.T.A.B. Sep. 9, 2022)
+ More Snippets
Document
IPR2022-01524, No. 1007 Exhibit - 1007 Adis (P.T.A.B. Sep. 9, 2022)
Cite Document
IPR2022-01524, No. 1007 Exhibit - 1007 Adis (P.T.A.B. Sep. 9, 2022)
+ More Snippets
Document
IPR2022-01524, No. 1055 Exhibit - 1055 Corporate Finance Institute (P.T.A.B. Sep. 9, 2022)
Cite Document
IPR2022-01524, No. 1055 Exhibit - 1055 Corporate Finance Institute (P.T.A.B. Sep. 9, 2022)
+ More Snippets
Document
IPR2022-01524, No. 1016 Exhibit - 1016 2009 10 Q (P.T.A.B. Sep. 9, 2022)
Cite Document
IPR2022-01524, No. 1016 Exhibit - 1016 2009 10 Q (P.T.A.B. Sep. 9, 2022)
+ More Snippets
Document
IPR2022-01524, No. 1044 Exhibit - 1044 Regeneron 28 September 2008 (P.T.A.B. Sep. 9, 2022)
Cite Document
IPR2022-01524, No. 1044 Exhibit - 1044 Regeneron 28 September 2008 (P.T.A.B. Sep. 9, 2022)
+ More Snippets
Document
IPR2022-01524, No. 1048 Exhibit - 1048 Bayer 19 August 2008 (P.T.A.B. Sep. 9, 2022)
Cite Document
IPR2022-01524, No. 1048 Exhibit - 1048 Bayer 19 August 2008 (P.T.A.B. Sep. 9, 2022)
+ More Snippets
Document
IPR2022-01524, No. 2008-2 Exhibit - File History of US Patent 10,857,205 Part 2 of 7 (P.T.A.B. Dec. 23, 2022)
Cite Document
IPR2022-01524, No. 2008-2 Exhibit - File History of US Patent 10,857,205 Part 2 of 7 (P.T.A.B. Dec. 23, 2022)
+ More Snippets
Document
IPR2022-01524, No. 2008-6 Exhibit - File History of US Patent 10,857,205 Part 6 of 7 (P.T.A.B. Dec. 23, 2022)
Cite Document
IPR2022-01524, No. 2008-6 Exhibit - File History of US Patent 10,857,205 Part 6 of 7 (P.T.A.B. Dec. 23, 2022)
+ More Snippets
Document
IPR2022-01524, No. 2014 Exhibit - Mylans Answer, Defenses, and Counterclaims to Plaintiff’s Complaint, Regeneron Pharms, Inc v Mylan Pharms Inc, Case No 122 cv 00061 TSK (P.T.A.B. Dec....
Cite Document
IPR2022-01524, No. 2014 Exhibit - Mylans Answer, Defenses, and Counterclaims to Plaintiff’s Complaint, Regeneron Pharms, Inc v Mylan Pharms Inc, Case No 122 cv 00061 TSK (P.T.A.B. Dec. 23, 2022)
+ More Snippets
Document
IPR2022-01524, No. 2022 Exhibit - Eylea aflibercept Injection label, revised May 2016 (P.T.A.B. Dec. 23, 2022)
Cite Document
IPR2022-01524, No. 2022 Exhibit - Eylea aflibercept Injection label, revised May 2016 (P.T.A.B. Dec. 23, 2022)
+ More Snippets
Document
IPR2022-01524, No. 2031 Exhibit - Petition for Inter Partes Review of US Patent No 9,254,338 B2, Mylan Pharms Inc v Regeneron Pharms, Inc, IPR2021 00881 (P.T.A.B. Dec. 23, 2022)
Cite Document
IPR2022-01524, No. 2031 Exhibit - Petition for Inter Partes Review of US Patent No 9,254,338 B2, Mylan Pharms Inc v Regeneron Pharms, Inc, IPR2021 00881 (P.T.A.B. Dec. 23, 2022)
+ More Snippets